Bilge Debeleç BÜTÜNER, Kemal Sami KORKMAZ

NKX3.1 binding to GPX2, QSCN6, SOD1, and SOD2 promoters contributes to antioxidant response regulation via transactivation

NKX3.1 is a prostate-specific transcription factor that is regulated by the androgen receptor in the presence of androgens. It functions as a tumor suppressor against the development of prostatic intraepithelial neoplasia and primary prostate tumors. Here, a recognized approach combining in silico analysis and chromatin immunoprecipitation (ChIP) was used to identify the genes directly regulated by NKX3.1 promoter binding in LNCaP cells. Quantitative PCR using ChIP-captured DNAs as templates verified a subset of NKX3.1 binding motifs. Thus, in the presence of androgens, significant NKX3.1 binding occurs to promoters of GPX2, QSCN6, SOD1, and SOD2 genes that contribute to oxidative stress regulation. Our data demonstrate that NKX3.1 is found in a DNA-bound state transiently at a basal level even in the absence of androgens; an increase in androgens promotes NKX3.1 binding, perhaps temporally rather than spatially, to the specific sites. The overall changes potentiate the transcriptional regulatory activity of NKX3.1, although they are dependent on the androgen receptor for the target promoters. The results suggest that NKX3.1 contributes to an antioxidant response by regulating the transcription of oxidative stress regulators by direct promoter binding.

Anahtar Kelimeler:

Chromatin immunoprecipitation, promoter binding, androgen, NKX3.1, MatInspector

NKX3.1 binding to GPX2, QSCN6, SOD1, and SOD2 promoters contributes to antioxidant response regulation via transactivation

Keywords:

Chromatin immunoprecipitation, promoter binding, androgen, NKX3.1, MatInspector,

PDF

___

Abate-Shen C, Shen MM, Gelmann E (2008). Integrating differentiation and cancer: the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Differentiation 76: 717–727.
Adamson E, de Belle I, Mittal S, Wang Y, Hayakawa J, Korkmaz K, O’Hagan D, McClelland M, Mercola D (2003). Egr1 signaling in prostate cancer. Cancer Biol Ther 2: 617–622.
Asselin J, Melancon R, Gourdea Y, Labrie F, Bonne C, Raynaud JP (1979). Specific binding of [3H]-methyltrienolone to both progestin and androgen binding components in human benign prostatic hypertrophy (BPH). J Steroid Biochem 10: 483–486.
Bar-Joseph Z, Gerber GK, Lee TI, Rinaldi NJ, Yoo JY, Robert F, Gordon DB, Fraenkel E, Jaakkola TS, Young RA et al. (2003). Computational discovery of gene modules and regulatory networks. Nat Biotechnol 21: 1337–1342.
Beier CP, Schmid C, Gorlia T, Kleinletzenberger C, Beier D, Grauer O, Steinbrecher A, Hirschmann B, Brawanski A, Dietmaier C et al. (2009). RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma—a phase II study. BMC Cancer 9: 308.
Bowen C, Ju JH, Lee JH, Paull TT, Gelmann EP (2013). Functional activation of ATM by the prostate cancer suppressor NKX3.1. Cell Rep 4: 516–529.
Bowen C, Stuart A, Ju JH, Tuan J, Blonder J, Conrads TP, Veenstra TD, Gelmann EP (2007). NKX3.1 homeodomain protein binds to topoisomerase I and enhances its activity. Cancer Res 67: 455–464.
Carson JA, Fillmore RA, Schwartz RJ, Zimmer WE (2000). The smooth muscle gamma-actin gene promoter is a molecular target for the mouse bagpipe homologue, mNkx3-1, and serum response factor. J Biol Chem 275: 39061–39072.
Cavin Perier R, Junier T, Bucher P (1998). The Eukaryotic Promoter Database EPD. Nucleic Acids Res 26: 353–357.
Coffey RN, Watson RW, O’Neill AJ, McEleny K, Fitzpatrick JM (2002). Androgen-mediated resistance to apoptosis. Prostate 53: 300–309.
Dryhurst D, McMullen B, Fazli L, Rennie PS, Ausio J (2012). Histone H2A.Z prepares the prostate specific antigen (PSA) gene for androgen receptor-mediated transcription and is upregulated in a model of prostate cancer progression. Cancer Lett 315: 38–47.
Erbaykent-Tepedelen B, Karamil S, Gonen-Korkmaz C, Korkmaz KS (2014). DNA damage response (DDR) via NKX3.1 expression in prostate cells. J Steroid Biochem Mol Biol 141: 26–36.
Hartemink AJ, Gifford DK, Jaakkola TS, Young RA (2001). Using graphical models and genomic expression data to statistically validate models of genetic regulatory networks. Pac Symp Biocomput: 422–33.
Hayakawa J, Mittal S, Wang Y, Korkmaz KS, Adamson E, English C, Ohmichi M, McClelland M, Mercola D (2004). Identification of promoters bound by c-Jun/ATF2 during rapid large-scale gene activation following genotoxic stress. Mol Cell 16: 521– 535.
Hecht A, Litterst CM, Huber O, Kemler R (1999). Functional characterization of multiple transactivating elements in beta- catenin, some of which interact with the TATA-binding protein in vitro. J Biol Chem 274: 18017–18025.
Korkmaz KS, Korkmaz CG, Ragnhildstveit E, Kizildag S, Pretlow TG, Saatcioglu F (2000a). Full-length cDNA sequence and genomic organization of human NKX3A—alternative forms and regulation by both androgens and estrogens. Gene 260: 25–36.
Korkmaz KS, Korkmaz CG, Ragnhildstveit E, Pretlow TG, Saatcioglu F (2000b). An efficient procedure for cloning hormone- responsive genes from a specific tissue. DNA Cell Biol 19: 499–506.
Lei Q, Jiao J, Xin L, Chang CJ, Wang S, Gao J, Gleave ME, Witte ON, Liu X, Wu H (2006). NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell 9: 367–378.
Li W, Meyer CA, Liu XS (2005). A hidden Markov model for analyzing ChIP-chip experiments on genome tiling arrays and its application to p53 binding sequences. Bioinformatics 21: i274–282.
Li Z, Van Calcar S, Qu C, Cavenee WK, Zhang MQ, Ren B (2003). A global transcriptional regulatory role for c-Myc in Burkitt’s lymphoma cells. Proc Natl Acad Sci U S A 100: 8164–8169.
Magee JA, Abdulkadir SA, Milbrandt J (2003). Haploinsufficiency at the Nkx3.1 locus. A paradigm for stochastic, dosage-sensitive gene regulation during tumor initiation. Cancer Cell 3: 273– 283.
Masuda K, Werner T, Maheshwari S, Frisch M, Oh S, Petrovics G, May K, Srikantan V, Srivastava S, Dobi A (2005). Androgen receptor binding sites identified by a GREF_GATA model. J Mol Biol 353: 763–771.
Mora GR, Prins GS, Mahesh VB (1996). Autoregulation of androgen receptor protein and messenger RNA in rat ventral prostate is protein synthesis dependent. J Steroid Biochem Mol Biol 58: 539–549.
Nelson PS, Clegg N, Arnold H, Ferguson C, Bonham M, White J, Hood L, Lin B (2002). The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci U S A 99: 11890–11895.
Ouyang X, DeWeese TL, Nelson WG, Abate-Shen C (2005). Loss- of-function of Nkx3.1 promotes increased oxidative damage in prostate carcinogenesis. Cancer Res 65: 6773–6779.
Ren B, Robert F, Wyrick JJ, Aparicio O, Jennings EG, Simon I, Zeitlinger J, Schreiber J, Hannett N, Kanin E et al. (2000). Genome-wide location and function of DNA binding proteins. Science 290: 2306–2309.
Ripple MO, Henry WF, Rago RP, Wilding G (1997). Prooxidant- antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J Natl Cancer Inst 89: 40–48.
Sato K, Tsuchiya N, Habuchi T, Satoh S, Shimoda N, Kato T (2003). Total cystoprostatectomy in the treatment of locally advanced prostate carcinoma. Aktuelle Urol 34: 259–261.
Schule R, Muller M, Kaltschmidt C, Renkawitz R (1988). Many transcription factors interact synergistically with steroid receptors. Science 242: 1418–1420.
Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin 63: 11–30.
Skotheim RI, Korkmaz KS, Klokk TI, Abeler VM, Korkmaz CG, Nesland JM, Fossa SD, Lothe RA, Saatcioglu F (2003). NKX3.1 expression is lost in testicular germ cell tumors. Am J Pathol 163: 2149–2154.
Steadman DJ, Giuffrida D, Gelmann EP (2000). DNA-binding sequence of the human prostate-specific homeodomain protein NKX3.1. Nucleic Acids Res 28: 2389–2395.
Sun H, Palaniswamy SK, Pohar TT, Jin VX, Huang TH, Davuluri RV (2006). MPromDb: an integrated resource for annotation and visualization of mammalian gene promoters and ChIP-chip experimental data. Nucleic Acids Res 34: D98–103.
Suzuki H, Ueda T, Ichikawa T, Ito H (2003). Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer 10: 209–216.
Truss M, Beato M (1993). Steroid hormone receptors: interaction with deoxyribonucleic acid and transcription factors. Endocr Rev 14: 459–479.
Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA, Jemal A, Ward E, Anderson RN, Edwards BK (2003). Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 95: 1276–1299.
Zhang H, Muders MH, Li J, Rinaldo F, Tindall DJ, Datta K (2008). Loss of NKX3.1 favors vascular endothelial growth factor-C expression in prostate cancer. Cancer Res 68: 8770–8778.